Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus chemotherapy for surgical conversion in unresectable stage IIIB-IIIC NSCLC
NCT06962189Phase 2Not yet recruiting
- Sponsor
- Zhejiang University
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of sintilimab in non-small cell lung cancer (NSCLC), sponsored by Zhejiang University. Planned start May 2025; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06962189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06962189.